NHS England

The AI Center created advanced AI algorithms using NHS medical pictures and patient data to give physicians tools to expedite and enhance diagnosis and care across many patient paths.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Medtronic is a global leader in healthcare technology, specializing in solutions for complex and chronic conditions. The company develops a wide range of medical technologies that address 70 different medical conditions, including treatments for the lungs, brain, heart, diabetes, and women's health. Its product offerings encompass patient monitoring systems, robotic surgery, insulin pumps, and cardiac devices, among others. Medtronic is committed to improving patient outcomes through innovative therapies and technologies that provide lifelong solutions, particularly for those suffering from chronic pain. With a focus on addressing diverse healthcare challenges, Medtronic leverages its extensive knowledge and dedication to enhance the lives of patients worldwide.

Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. By utilizing an intelligent agent, Mendelian analyzes patients' clinical features to identify the genes responsible for rare conditions. Physicians input phenotypic details, and the platform generates outputs that indicate potential causative genes and mutations. This innovative approach enhances the investigation of undiagnosed cases, allowing for earlier detection and treatment of rare diseases through machine learning and knowledge reasoning.

Tommy's is a charity that carries out research into the causes of miscarriage, stillbirth, and premature birth. They support them throughout their entire pregnancy journey from conception to postpartum recovery. Their free digital tools, calculators, and resources will help them have a healthy and happy pregnancy. All the information and support they need, including tools and news, and stories covering the entire pregnancy.

Oxford Cancer Biomarkers specializes in the development and commercialization of colorectal cancer biomarker tests aimed at enhancing treatment pathways. Associated with the Institute of Cancer Medicine at Oxford University, the company leverages its founders' expertise in translational cancer science. It has formed partnerships with pharmaceutical companies to utilize its discovery platforms, CancerNav® and ToxNav™, in the creation of companion diagnostic tests for emerging therapies. The tests developed by Oxford Cancer Biomarkers assess dihydropyridine dehydrogenase deficiency and related variants, which are linked to partial dihydropyrimidine deficiency and increased toxicity risks. This innovation enables healthcare providers and patients to analyze resected tissue samples to evaluate the likelihood of cancer relapse, thereby advancing personalized medicine in oncology.

icometrix is a company that specializes in the analysis of brain MRI scans to enhance personalized care for patients with neurological disorders. Founded in 2011 as a spin-off from the universities and university hospitals of Leuven and Antwerp, icometrix is headquartered in Leuven, Belgium, with an additional office in Boston, USA. The company has developed MSmetrix, a tool that identifies brain lesions, measures lesion volume, and assesses whole brain and grey matter volume and atrophy. MSmetrix has received market approval in the EU and several other countries, with FDA clearance pending. icometrix is recognized as a leader in MRI biomarkers for routine clinical practice and is certified in quality management and information security. Additionally, the company provides image analysis services for clinical trials and research studies, utilizing its software-as-a-service model to process large volumes of brain imaging data. This approach aids in advancing research on various neurological conditions, including traumatic brain injury, epilepsy, Alzheimer’s disease, and stroke, by using imaging biomarker outcomes as key endpoints in drug development.

Royal United Hospital Bath NHS Foundation Trust provides acute treatment and cares for people in Bath and the surrounding towns.

Cibiltech specializes in developing digital solutions aimed at enhancing predictive medicine for renal transplantation. By leveraging advanced algorithms, the company provides nephrologists with tools to assess the individual graft loss trajectory of kidney transplant patients. This capability allows for tailored treatment adjustments, ultimately leading to longer graft survival and improved patient lifespans. Additionally, Cibiltech's healthcare application facilitates personalized patient care and effective clinical research through artificial intelligence. It enables risk stratification and remote monitoring, streamlining the medical workflow and empowering clinicians to anticipate health outcomes. As a result, medical decisions are improved, supporting more personalized treatment strategies for kidney transplant patients.

InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.

Optos plc is a manufacturer of advanced retinal imaging devices aimed at enhancing patient care in the eyecare sector. The company specializes in ultra-widefield, high-resolution digital imaging, producing optomaps that capture approximately 82% of the retina in a single image, a capability unmatched by other devices. Optos offers a diverse range of imaging products tailored for various customer segments and patient needs. The P200 and 200Dx devices are designed for wellness screening by optometrists and ophthalmologists in primary care, while the P200C devices cater to the more demanding clinical imaging requirements in secondary care and those managing advanced ocular diseases. Additionally, the P200MA and 200Tx devices support ophthalmologists and retinal specialists in delivering medical care. By providing these innovative tools, Optos enables eyecare professionals to discover, diagnose, document, and treat ocular pathologies that may otherwise go unnoticed with traditional examination techniques.

Inovus Ltd is a company based in Saint Helens, United Kingdom, that specializes in designing and manufacturing medical simulation products aimed at enhancing surgical training. Founded in 2012, the company offers a variety of simulators, including take-home laparoscopic simulators and institutional models, which focus on essential surgical techniques such as laparoscopic appendectomy and cholecystectomy. Inovus Ltd's products are tailored for surgical trainees and residents, providing them with accessible and versatile training options that improve their skills in critical care, medicine, and surgery. The company's commitment to advancing surgical education enables clinicians to deliver better patient care through improved training resources.

Corporation Pop designs original and engaging interactive tools that help their clients communicate with their audience. Founded in 2007, the company is headquartered in Manchester, Manchester, United Kingdom.

Blue Maestro is a leading designer and developer of connected products and solutions, from consumer devices through to their work with NHS England on the next generation of medicine adherence sensors. They have a number of innovative products and solutions under development, several that are patent pending. Meet some of Blue Maestro’s management team below.